"We have continued to execute well across our business, including the achievement of key clinical program milestones, since the start of 2025," said Lance Alstodt, Chief Executive Officer of BioRestorative. "Moving forward, we remain focused on aggressively executing our growth strategy while carefully managing our resources, and see many potential value enhancing inflection points ahead." Recent Highlights MELVILLE, N.Y., Aug. 12, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", " ...

Core Insights - BioRestorative Therapies, Inc. has presented preliminary data from its Phase 2 clinical trial of BRTX-100 for chronic lumbar disc disease, showing promising safety and efficacy results [1][3] Group 1: Clinical Trial Data - The ongoing Phase 2 trial of BRTX-100 has shown no serious adverse events and no dose-limiting toxicity at 26-104 weeks [2] - The trial data indicates trends of over 30% improvement in both the Oswestry Disability Index (ODI) and Visual Analog Scale (VAS), with significant improvements observed at various weeks [3] - The percentage of subjects showing greater than 50% improvement in both ODI and VAS is as follows: - Week 2: 0.0% - Week 12: 13.33% - Week 26: 46.15% - Week 52: 70.0% - Week 104: 66.66% [3] Group 2: Product and Company Overview - BRTX-100 is a novel cell-based therapeutic designed to treat areas with low blood flow, specifically targeting chronic lumbar disc disease [5] - The company is conducting a randomized, double-blinded, and controlled study with up to 99 eligible subjects across 16 clinical sites in the U.S. [5] - BioRestorative develops therapeutic products using adult stem cells, focusing on disc/spine disease and metabolic disorders, along with a commercial BioCosmeceutical platform [6][7][8]

Core Insights - BioRestorative Therapies, Inc. is advancing its Phase 2 clinical trial of BRTX-100 for chronic lumbar disc disease, with an update to be presented at the ISCT 2025 Annual Meeting [1][2] Company Overview - BioRestorative is focused on regenerative medicine, particularly stem cell-based therapies and products [1][5] - The company has two main clinical development programs: the Disc/Spine Program and the Metabolic Program [5][6] BRTX-100 Details - BRTX-100 is a cell-based therapeutic targeting areas with low blood flow, currently in a Phase 2 clinical trial for chronic lumbar disc disease [4] - The FDA has granted Fast Track designation to BRTX-100, indicating positive preliminary safety and efficacy data [4] - The FDA also cleared the IND application for BRTX-100 to treat chronic cervical discogenic pain, expanding its clinical pipeline [4] Presentation Information - The clinical update on BRTX-100 will be presented by Francisco Silva at the ISCT 2025 Annual Meeting on May 8, 2025 [3] Additional Programs - The Metabolic Program focuses on therapies targeting obesity and metabolic disorders using brown adipose-derived stem cells [6] - BioRestorative also operates a BioCosmeceutical platform, developing products aimed at cosmetic applications [7]